Breaking Clinical Trial Myopia Treatment OCT changes with low-level red light therapy for myopia in children Ağustos 26, 2025
Breaking Cataract Patient Education Recommendation Surgery Treatment Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery Eylül 10, 2025
Breaking Cornea Innovation Patient Education Treatment Surgical innovation in dry eye disease: Salivary gland transplant Ağustos 27, 2025
Breaking Cataract Cornea Hyperopia LASIK Myopia Patient Education PRK Surgery Next-generation IOLs advance complex cataract care Ağustos 26, 2025
Home Patient Education Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye – Nature Share your love
Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial | Eye Nature Source: Author: | Date: 2025-07-15 07:00:00 Source: Author: | Date: 2025-07-15 07:00:00 Share your love Previous Yazı Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye - Nature Next Yazı Infographic: landmark trials in neuro-ophthalmology – results of the REVERSE trial for unilateral gene therapy rAAV2/2-ND4 in leber hereditary optic neuropathy - Nature Related Posts FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025 AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025 Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology TimesEkim 3, 2025 Leave a ReplyCancel ReplyE-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Yorum gönder
FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa | Ophthalmology TimesEkim 3, 2025
AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA | Ophthalmology TimesEkim 3, 2025
